Description
Description: This assay employs a two-site sandwich ELISA to quantitate FMNL3 in samples. An antibody specific for FMNL3 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any FMNL3 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for FMNL3 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of FMNL3 bound in the initial step. The color development is stopped and the intensity of the color is measured.
Overview: FMNL3 contains a formin homology 2 domain and has high sequence identity to the mouse Wbp3 protein. Two alternative transcripts encoding different isoforms have been described.
FMNL is a 5'-truncated partial cDNA encoding a Formin-homology protein related to DAAM1, DAAM2, DIAPH1 and DIAPH2.FMNL1 mRNA was expressed in natural killer cells, Burkitt lymphoma, pancreatic cancer, prostate cancer, and lung large cell carcinoma, FMNL2 mRNA in several normal tissues, diffuse-type gastric cancer, breast cancer, chondrosarcoma, melanoma, and glioblastoma, and FMNL3 mRNA in gastric cancer. FMNL1, FMNL2 and FMNL3 might be implicated in polarity control, invasion, migration, or metastasis through regulation of the Rho-related signaling pathway